Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humoral and Cellular Responses to BNT162b2 in Elderly
NCT04961502Unknown
- Sponsor
- Gérond'if
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Gérond'if. Primary endpoint: Plasma concentration of anti-RBD IgG antibodies at 50 days. Status: unknown.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04961502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961502.